Methamphetamine, often simply referred to as “meth,” has evolved into a global public health crisis of staggering proportions. Its devastating impact cuts across borders, affecting millions through addiction, crime, and profound social disintegration. From record-breaking drug seizures to dangerous new forms of the substance, the meth epidemic is a complex and urgent challenge that demands a comprehensive response
The Meth Crisis by the Numbers
The scale of the methamphetamine problem is immense. The United Nations Office on Drugs and Crime’s 2025 World Drug Report estimated that in 2023 alone, roughly 31 million people used amphetamines, including methamphetamine, accounting for 0.6% of the global population aged 15 to 64. Qualitative assessments indicate that amphetamine use has been on the rise both in 2023 and over the past decade. The highest usage numbers are found in East and Southeast Asia, while North America reports the highest prevalence rate. Globally, methamphetamine remains the primary substance seized by law enforcement.
In the United States, the situation remains critical. While overall overdose deaths fell to roughly 68,000 in the 12-month period ending in October 2025—the lowest since before the pandemic—psychostimulants like methamphetamine were the second largest category in overdose deaths, accounting for nearly 26,000 fatalities. This figure exceeds cocaine-related deaths, which stood at nearly 19,000. The decline in overall overdose deaths has been largely driven by a sharp drop in opioid fatalities, but methamphetamine-related deaths have not seen the same level of decrease.
The Deadly Consequence of Polydrug Use
One of the most alarming trends is the simultaneous use of methamphetamine and opioids. A 2025 study published in Addictive Behaviors Reports surveyed 414 people who use illicit drugs in Nevada and New Mexico and found that over half (53.1%) reported deliberately using both drugs together. Those engaged in simultaneous use exhibited the highest rates of homelessness, trauma, and incarceration, making them an exceptionally vulnerable population.
This combination of methamphetamine and opioids—often referred to as “goofballs”—creates a synergistic effect that drastically increases the risk of fatal overdose. The widespread availability of potent synthetic opioids like fentanyl has only exacerbated this danger, leading to what experts describe as a “resurgent” stimulant epidemic intertwined with the ongoing opioid crisis.
The Global Supply and “Super Meth”
The production and trafficking of methamphetamine have become increasingly sophisticated and globalized. The illicit manufacture from the Golden Triangle, a region straddling Myanmar, Laos, and Thailand, has grown exponentially. A report released by the UNODC in May 2025 revealed a record amount of methamphetamine seizures in East and Southeast Asia, totaling 236 tons—a 24% increase compared to 2023. As a UNODC official noted, this figure represents only the amount seized, and “much more methamphetamine is actually reaching the market”.
This trafficking network is vast and far-reaching. For instance, in April 2026, India’s Narcotics Control Bureau arrested a key Myanmar-based trafficker linked to the seizure of 48 kg of crystal meth, one of the largest consignments trafficked from Myanmar. Such seizures are part of a broader crackdown; in 2025 alone, the NCB registered 48 NDPS cases and arrested 116 drug traffickers, seizing massive quantities of crystal meth, methamphetamine powder, and heroin.
Furthermore, the nature of the drug itself is changing. Since the U.S. Congress passed the Combat Methamphetamine Epidemic Act in 2006, which restricted access to pseudoephedrine, illicit manufacturers have shifted to a new method using phenyl-2-propanone (P2P). This has enabled the creation of large-scale “super labs” producing a form often called “super meth.” P2P meth is frequently more potent, more pure, and cheaper than ever before. This manufacturing shift has led to a drug that can cause severe side effects, psychosis, organ damage, and addiction, presenting a major new challenge for public health systems.
Health Impacts and Gender Disparities
The health consequences of methamphetamine addiction are severe and multifaceted. A study among adult patients at Sri Lanka’s National Institute of Mental Health found that the most cited physical impacts were weight loss (38.88%) and loss of appetite (37.24%). Mental health effects were also pronounced, with irritability (28.81%) and interpersonal relationship problems (50.82%) being common complaints. The UNODC has also highlighted significant gender disparities, noting that women receiving treatment for methamphetamine use disorder often have more severe symptoms and a greater psychological burden, including more adverse childhood experiences. They are also more prone to high-risk sexual behaviors, increasing their risk of contracting HIV, viral hepatitis, and other infectious diseases.
The addiction also has profound social and economic ripple effects. Research on Afghan migrants in Peshawar found that displacement trauma, economic difficulties, and societal discrimination are key drivers of methamphetamine use. The resulting addiction leads to financial problems, deteriorating health, and fractured family and social relationships.
Hope for Treatment and Recovery
Despite the grim statistics, there are reasons for hope. The field of addiction medicine is making significant strides in developing effective treatments. While there are currently no FDA-approved medications specifically for methamphetamine use disorder, promising research is underway. A phase 3 clinical trial published in JAMA Psychiatry in 2025 found that the antidepressant mirtazapine significantly reduced methamphetamine use in adults with moderate to severe methamphetamine use disorder. Over a 12-week period, patients receiving mirtazapine reduced their methamphetamine use by an average of 7 days per month, compared to a reduction of 4.8 days in the placebo group. The drug was found to be safe, with the most common side effects being drowsiness and weight gain.
Beyond pharmacotherapy, behavioral therapies remain the cornerstone of treatment. Cognitive Behavioral Therapy (CBT) helps patients recognize and correct harmful behavior patterns, while Contingency Management (CM) uses positive reinforcement to encourage abstinence. The Matrix Model, an intensive outpatient treatment approach, has also shown effectiveness. Professional treatment programs can be provided in inpatient or outpatient settings, and long-term support is crucial for preventing relapse.
A Path Forward
The methamphetamine crisis is a complex, multi-faceted problem that requires a coordinated global response. This includes stronger international cooperation to disrupt trafficking networks, targeted public health interventions to reduce harm and support treatment, and ongoing research into new pharmacological and behavioral therapies. While the challenge is immense, the recent declines in overall overdose deaths and the development of new treatment options offer a glimmer of hope. With sustained effort and compassion, it is possible to curb the tide of this devastating epidemic and support individuals and communities in their journey toward recovery.